Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct

In a two-part series, this first paper outlines the quality and regulatory thinking that underpins RBQM, and details essential points of compliance for emerging ICH core guidances on RBQM—including ICH E8 (R1) and ICH GCP E6 (R3)—and offers further discussion of RBQM implications for sponsors, clinical sites and patients.n a two-part series, this first paper outlines the quality and regulatory thinking that underpins RBQM, and details essential points of compliance for emerging ICH core guidances on RBQM—including ICH E8 (R1) and ICH GCP E6 (R3)—and offers further discussion of RBQM implications for sponsors, clinical sites and patients. n a two-part series, this first paper outlines the quality and regulatory thinking that underpins RBQM, and details essential points of compliance for emerging ICH core guidances on RBQM—including ICH E8 (R1) and ICH GCP E6 (R3)—and offers further discussion of RBQM implications for sponsors, clinical sites and patients.


Open PDF

Return to Insights Center

Related Insights

Related Insights

Video

Part 2: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021

Video

Part 3: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Article

Decentralized trial tools and technologies are here to stay: A regulatory perspective

Jul 23, 2021

Video

How to transition existing trials under EU-CTR

Feb 1, 2023

Show more